^
    Back
    Association details:
    Biomarker:EGFR T790M + EGFR C797S
    Cancer:Lung Adenocarcinoma
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    J Clin Invest
    Title:

    Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma

    Published date:
    02/03/2020
    Excerpt:
    ...with EGFRT790M and EGFRC797S mutations, were highly responsive to the combined treatment of Notch inhibitors with gefitinib or osimertinib, respectively…
    Secondary therapy:
    Notch Inhibitor
    DOI:
    10.1172/JCI126896